Bespoke brightening skincare manufacturing

Private label brightening serums for radiance, not lightening

Radiance and an even-looking tone are the aim of every bespoke brightening serum, vitamin C serum, tone cream, essence, spot serum and body lotion we develop and make in our Leicester facility, as a private label brightening serum manufacturer for premium wellness brands selling in the UK, the EU and the US. Each product is built to your brief rather than a stock formula with a new label: the actives and their levels, the base, texture, colour stability and pack, with stability and safety data behind them. Your formula is yours, with its specification and data, as our formula ownership commitment sets out.

• Brightening serums. Tranexamic acid, alpha-arbutin, niacinamide or vitamin C derivatives, alone or layered in one water-based serum.
• Vitamin C serums. L-ascorbic acid at low pH, or stable derivatives such as ascorbyl glucoside and 3-O-ethyl ascorbic acid; our page on active serum manufacturing covers the wider range.
• Tone creams and essences. Daily moisturisers and essences for radiance and an even-looking tone, with SPF for the UK and the EU through our sun care manufacturing.
• Spot serums. Concentrated serums in precision applicators for the look of dark spots.
• Body brightening. Lotions for an even-looking tone on the body, with alpha-arbutin within its body lotion limit, niacinamide and tranexamic acid, alongside our body care manufacturing.
• Exfoliating tone products. Gentle acids for smoother, brighter-looking skin, with sun protection directions on every AHA label.

We make brightening products, not skin lighteners. Every claim describes radiance and how even skin tone looks, never a change to anyone's natural skin colour. Brightening sits within our skincare and cosmetic manufacturing, so a serum can launch with a matching routine. We also develop and make scalp care and haircare.

How a brightening project runs

Our research and development team runs each project from brief to scale-up. We map your claims to actives that work at different steps of pigment formation, then make prototypes at levels within each market's limits for you to judge on texture, finish and feel. The lead sample goes through a colour-stability screen under light and warm storage before it enters stability in its final pack, and a pilot batch confirms the process before the first production run. R&D is a paid stage that can be included with an order of the right size.

Where each brightening active acts on melanin

Skin colour comes from melanin, made by melanocytes with the enzyme tyrosinase and passed to the surrounding skin cells in packages called melanosomes. Brightening actives act at different steps of that process, which is why layered formulas make sense.

The actives, step by step

The evidence differs by active. Niacinamide has the clearest human data: in a split-face, double-blind trial in 50 women aged 40 to 60, a moisturiser with 5% niacinamide improved the look of spots and yellowing against the same moisturiser without it (Bissett and colleagues, 2004), and laboratory work explains why (Hakozaki and colleagues, 2002). For topical tranexamic acid, a dermatology review found the data limited by small samples, short study periods and no dose comparisons, and the human studies it covered enrolled people with a pigment condition, not cosmetic users (Sheu, Cutis, 2018). So we use it for its stability and tolerance, and test the claim on your product.

Colour and stability work

Many brightening actives change colour as they age, so colour stability is designed in from the first sample. Vitamin C browns as it oxidises and loses activity. Kojic acid yellows and browns, faster in light and heat (Ayuhastuti and colleagues, 2024). Alpha-arbutin can break down to hydroquinone, which the EU holds to trace levels. We answer with chelators that bind trace metals, antioxidants, nitrogen and low headspace during compounding and filling, a pH held inside each active's window, and airless or opaque packs. Colour is read with an instrument against the approved standard at release and through stability, and a colour tolerance in the specification catches drift before a customer sees it. Where a brief needs a clear pack or a long shelf life, we switch to colour-stable forms such as vitamin C derivatives or kojic acid dipalmitate.

Layering and compatibility

Tranexamic acid and niacinamide pair well near skin pH. L-ascorbic acid entered skin only when formulated below pH 3.5 in pig skin studies (Pinnell and colleagues, 2001), so it sits in its own low-pH serum or an anhydrous base. Copper ions speed the breakdown of vitamin C, and exfoliating acids raise sun sensitivity, so we screen every combination against the pH window, the pack and the claims, and check the finished formula for tolerance.

Chelators, nitrogen and a colour check on every batch

1. Specify. We agree actives, grades and levels for each market, the pH window, colour standard, claims, pack and shelf life, and screen every ingredient against each market's annexes.
2. Approve suppliers. Every material comes from a supplier approved before use and reviewed every year, with a certificate of analysis checked for every lot, including residual hydroquinone for arbutin lots.
3. Compound. Water phases are prepared with a chelator, emulsions are built phase by phase, and heat-sensitive actives go in as the batch cools. Vitamin C and kojic acid formulas are made and filled under nitrogen with low headspace and reduced light.
4. Adjust and check. pH is adjusted into its window and colour is read against the standard on every batch, with appearance, odour, viscosity and fill weight.
5. Fill and label. Products are filled into airless pumps, amber or opaque droppers or tubes, and labels are verified on every batch.
6. Test, retain and release. Every batch is tested by accredited partner laboratories (ISO/IEC 17025) as part of every order, including an assay of the label-claimed actives and, for arbutin products, residual hydroquinone; three retained samples per batch are kept for shelf life plus one year, and quality control releases every batch against its specification.

Packs that keep colour

Our packaging development team fills serums into airless pumps or amber and opaque glass, and creams into airless jars or laminate tubes; clear packs are approved only after light testing. Every pack passes compatibility testing with your formula, and every unit carries its batch code and either a best before date or a period-after-opening symbol, set by the stability results.

Assays, hydroquinone results and colour data

Each product comes with its documents: the specification and colour standard, a certificate of analysis for every batch with active assays and, for arbutin products, residual hydroquinone, the stability and colour data behind your shelf life, the cosmetic product safety report (CPSR), and the product information file built with you for your Responsible Person.

Hydroquinone traces, colour drift and photography for tone claims

Before launch, every product has a CPSR, signed by a qualified safety assessor who compares each ingredient's expected exposure with its safety data. For brightening, the assessor checks each active against its limit for the product type, hydroquinone traces in arbutin products and the combined tolerance of layered actives. We run the test programme with accredited partner laboratories:

• Stability in the final pack, accelerated and real-time, with light exposure, tracking colour by instrument, odour, pH, viscosity, active content and residual hydroquinone. Our stability and shelf life testing page sets out the method.
• Compatibility between formula and pack: no leaching, swelling, discolouring or oxygen ingress.
• Challenge testing to ISO 11930 for every product that contains water.
• Microbiology on finished product, against the limits your specification sets.
• Claims tests, arranged with specialist partners: standardised photography under controlled light, instrumental colour readings of spots and overall tone, expert grading, consumer perception tests and dermatologist-supervised patch tests.

We make every brightening product in our Leicester facility. We are ISO 9001 certified by BSI, and the scope of our certificate, FS 822806, includes cosmetics.

Arbutin and kojic acid limits, and the US line on lightening

Brightening sells as a cosmetic in all three markets when its claims describe radiance and how even skin tone looks. This is the position as of October 2026.

• Great Britain. We arrange the CPSR and build the product file for your UK Responsible Person, who notifies the product through SCPN before sale. Kojic acid is capped at 1% in face and hand products, as in the EU. Great Britain sets no specific arbutin limits, so we formulate to the EU limits for brands that sell in both.
• European Union and Northern Ireland. The same file supports CPNP notification by your Responsible Person in the EU, or in Northern Ireland for that market. The arbutin, alpha-arbutin and kojic acid limits above apply, and EU labels carry the expanded fragrance allergen list.
• United States. FDA says every over-the-counter skin lightening product needs its approval as a new drug before it can be sold (FDA), so US labels stay with radiance and the look of an even tone. Cosmetics need facility registration and product listing under MoCRA. Our FDA registration is a food facility registration for dietary supplements, so we register our Leicester facility under MoCRA as US brightening programmes start.

Hydroquinone, mercury and corticosteroids are banned from skin care products in the UK and the EU, and we never use them. Strong brightening claims are specific and tested: "brighter-looking skin", "a more even-looking tone", "dark spots look less visible", each backed by imaging or colour readings. Start your project with your actives, claims and markets.

References: Commission Regulation (EU) 2024/996 on vitamin A, arbutin and other substances (2024); The Cosmetic Products (Restriction of Chemical Substances) (No. 2) Regulations 2024 (2024); Hakozaki and colleagues, British Journal of Dermatology (2002); Bissett and colleagues, International Journal of Cosmetic Science (2004); Ayuhastuti and colleagues, Cosmetics (2024); Sheu, Cutis (2018); Pinnell and colleagues, Dermatologic Surgery (2001); US FDA, action on over-the-counter skin lightening products (2022).